3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Neuroendocrine Tumors
169
Carcinoma, Neuroendocrine
73
Thyroid Neoplasms
52
Pheochromocytoma
45
Thyroid Carcinoma, Anaplastic
42
Thyroid Cancer, Papillary
42
Adrenocortical Carcinoma
40
Carcinoid Tumor
39
Paraganglioma
35
Adenocarcinoma, Follicular
33
Neoplasm Metastasis
29
Neoplasms
28
Somatostatinoma
26
Adenoma, Islet Cell
26
Insulinoma
22
Carcinoma, Medullary
22
Carcinoma, Islet Cell
22
Pancreatic Neoplasms
21
Pituitary Neoplasms
20
Sarcoma
19
Glucagonoma
19
Gastrinoma
19
Gastro-enteropancreatic neuroendocrine tumor
16
Head and Neck Neoplasms
15
Colorectal Neoplasms
14
Multiple Endocrine Neoplasia Type 1
13
Neuroblastoma
12
Carcinoma, Renal Cell
12
Carcinoma, Non-Small-Cell Lung
12
Vipoma
11
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Endocrine
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled